Positive Analyst Ratings and Price Targets for 4D Molecular Therapeutics
As of February 7, 2024, 4D Molecular Therapeutics (NASDAQ:FDMT) has garnered favorable analyst ratings. The consensus among 5 Wall Street ...
As of February 7, 2024, 4D Molecular Therapeutics (NASDAQ:FDMT) has garnered favorable analyst ratings. The consensus among 5 Wall Street ...
On February 6, 2024, 4D Molecular Therapeutics (4DMT) unveiled promising preliminary findings from the Phase 2 PRISM clinical trial, which ...
On January 23, 2024, 4D Molecular Therapeutics (4DMT) celebrated a significant milestone as they were granted the esteemed Rare Pediatric ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.